IFNAR1 | Interferon (alpha, beta and omega) receptor 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IFNAR2 | Interferon (alpha, beta and omega) receptor 2 | Cancer-related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
IFNGR1 | Interferon gamma receptor 1 | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IFNGR2 | Interferon gamma receptor 2 (interferon gamma transducer 1) | Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
IGF1R | Insulin-like growth factor 1 receptor | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
IL11RA | Interleukin 11 receptor, alpha | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL17A | Interleukin 17A | Cancer-related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
IL1B | Interleukin 1, beta | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
IL1R1 | Interleukin 1 receptor, type I | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL3RA | Interleukin 3 receptor, alpha (low affinity) | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL6R | Interleukin 6 receptor | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
INSR | Insulin receptor | CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGA4 | Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAV | Integrin, alpha V | Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
ITGB3 | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
M6PR | Mannose-6-phosphate receptor (cation dependent) | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
MC2R | Melanocortin 2 receptor (adrenocorticotropic hormone) | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
MPL | MPL proto-oncogene, thrombopoietin receptor | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Not detected |
MR1 | Major histocompatibility complex, class I-related | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
MS4A2 | Membrane-spanning 4-domains, subfamily A, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
OXTR | Oxytocin receptor | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PGF | Placental growth factor | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PLAT | Plasminogen activator, tissue | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Mixed |
PLAU | Plasminogen activator, urokinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
PLAUR | Plasminogen activator, urokinase receptor | Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PLG | Plasminogen | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PLIN3 | Perilipin 3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRLR | Prolactin receptor | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PTH2R | Parathyroid hormone 2 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
RAMP1 | Receptor (G protein-coupled) activity modifying protein 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
RAMP2 | Receptor (G protein-coupled) activity modifying protein 2 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
RAMP3 | Receptor (G protein-coupled) activity modifying protein 3 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
SCTR | Secretin receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Group enriched |
SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SERPINC1 | Serpin peptidase inhibitor, clade C (antithrombin), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SERPIND1 | Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SERPINE1 | Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SNAP25 | Synaptosomal-associated protein, 25kDa | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Tissue enriched |
SYT2 | Synaptotagmin II | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TLR2 | Toll-like receptor 2 | CD markers FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TNF | Tumor necrosis factor | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |